Table 7.

Application of the Marin model to the current study group




Estimated 4-y rate, %
Study and risk group
No. (%)
Progression-free
Survival
University of Texas M. D. Anderson*    
    Good   132 (60)   94   96  
    Intermediate   60 (27)   72   86  
    Poor   27 (12)   30   49  
Marin38     
    Good   108 (49)   93   94  
    Intermediate   87 (39)   61   75  
    Poor
 
26 (12)
 
89
 
100
 



Estimated 4-y rate, %
Study and risk group
No. (%)
Progression-free
Survival
University of Texas M. D. Anderson*    
    Good   132 (60)   94   96  
    Intermediate   60 (27)   72   86  
    Poor   27 (12)   30   49  
Marin38     
    Good   108 (49)   93   94  
    Intermediate   87 (39)   61   75  
    Poor
 
26 (12)
 
89
 
100
 

Adverse factors: prior hematologic resistance to IFN-α, splenomegaly, and no cytogenetic response to imatinib mesylate (Ph- positive > 90%) after 3 months of imatinib mesylate therapy.

*

Good indicates no adverse factors; intermediate, 1 adverse factor; poor, 2 or 3 adverse factors.

or Create an Account

Close Modal
Close Modal